공간생물학 및 멀티오믹스 시장 예측(2034년) - 분자 모달리티, 기술, 멀티오믹스 조합, 제품 및 서비스, 샘플 유형, 용도 및 지역별 분석

According to Stratistics MRC, the Global Spatial Biology & Multi-Omics Market is accounted for $2.4 billion in 2026 and is expected to reach $7.0 billion by 2034 growing at a CAGR of 14.3% during the forecast period. Spatial biology and multi-omics refer to advanced analytical techniques that map the spatial distribution of multiple biological molecules within intact tissue samples. They function by integrating genomic, transcriptomic, proteomic, and metabolomic data to provide a comprehensive understanding of cellular interactions and tissue architecture. These technologies utilize high-resolution imaging, sequencing, and mass spectrometry to preserve spatial context while analyzing complex biological systems. Their application enables researchers to uncover disease mechanisms, identify novel biomarkers, and develop targeted therapeutic interventions with unprecedented precision.

Market Dynamics:

Driver:

Rising Demand for Precision Medicine

The escalating global emphasis on precision medicine compels researchers to adopt spatial biology and multi-omics platforms offering detailed cellular analysis alternatives. Growing recognition of tumor heterogeneity and complex disease mechanisms is accelerating the integration of these technologies into drug development frameworks. This transition is supported by advancements in imaging resolution, which enhance data accuracy. Consequently, pharmaceutical firms are investing in multi-omics technologies to achieve compliance with efficacy benchmarks while optimizing therapeutic development costs.

Restraint:

High Instrumentation and Data Analysis Costs

The substantial expenses associated with acquiring and operating advanced spatial biology instruments represent a significant barrier to widespread commercial adoption. Developing highly accurate multi-omic datasets often requires complex imaging processes and sophisticated bioinformatics techniques, which escalate overall research costs. Furthermore, the variability in tissue sample preparation limits the operational reliability of standardized analytical pipelines. These factors collectively constrain market expansion, particularly for smaller laboratories with limited funding budgets.

Opportunity:

Expansion in Oncology Research Applications

The oncology research sector presents substantial growth opportunities for spatial biology and multi-omics providers due to increasing demand for tumor microenvironment analysis. Advanced imaging platforms offer a highly effective pathway to map immune cell interactions without destroying tissue architecture, utilizing high-resolution sequencing as primary inputs. As global investments in cancer immunotherapy expand, the adoption of advanced multi-omics solutions is expected to surge significantly.

Threat:

Competition from Traditional Bulk Sequencing

The continuous reliance on traditional bulk sequencing methodologies poses a considerable threat to the spatial biology and multi-omics market. Conventional bulk RNA sequencing and established proteomic assays often exhibit superior cost-effectiveness under current research budgets and can be more economically viable for large-scale population studies. Additionally, the rapid advancement of single-cell sequencing technologies is enhancing the efficiency of conventional cellular analysis methods. This competitive pressure may hinder market penetration.

Covid-19 Impact:

The pandemic initially disrupted laboratory operations and delayed research projects due to facility closures. However, the subsequent need for rapid viral pathogenesis understanding accelerated the adoption of spatial biology platforms for tissue analysis. Post-pandemic, the heightened focus on infectious disease research and immunology has reinforced long-term investments in multi-omics technologies, driving robust market recovery and expansion across diverse academic and pharmaceutical sectors globally.

The spatial transcriptomics segment is expected to be the largest during the forecast period

The spatial transcriptomics segment is expected to account for the largest market share during the forecast period, due to its foundational role and widespread applicability across diverse biological research environments. Spatial transcriptomics platforms offer exceptional gene expression mapping and operate effectively in analyzing complex tissue sections, which significantly reduces data loss and minimizes spatial context disruption in daily research processes. As industries increasingly prioritize detailed cellular analysis methods, the demand for specialized transcriptomics tools continues to surge, thereby solidifying its dominant market position.

The hybrid imaging-sequencing technologies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hybrid imaging-sequencing technologies segment is predicted to witness the highest growth rate, driven by rapid advancements in optical engineering and molecular biology integration. These technologies enable the precise correlation of morphological features to produce highly specialized and robust multi-omic outputs tailored for specific disease applications. The ability to enhance data resolution, operational scalability, and analytical depth through advanced hybrid integration significantly improves process economics, accelerating commercial adoption globally.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the presence of well-established pharmaceutical industries and advanced research infrastructure that heavily utilize spatial biology and multi-omics. The region benefits from substantial research and development investments, robust intellectual property protection, and supportive government initiatives promoting technological innovation in healthcare. Furthermore, the early adoption of advanced multi-omics platforms by key industry players in the United States and Canada reinforces the region's dominant position globally.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapid pharmaceutical modernization and expanding biotechnology sectors in emerging economies. Countries such as China, India, and Japan are increasingly investing in research infrastructure and multi-omics technologies to meet growing domestic healthcare demands and stringent efficiency regulations. Additionally, favorable government policies, rising foreign direct investment, and the availability of cost-effective technological resources are collectively driving the accelerated adoption of spatial biology across the region.

Key players in the market

Some of the key players in Spatial Biology & Multi-Omics Market include 10x Genomics, Inc., Bruker Corporation, Illumina, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Quanterix Corporation, NanoString Technologies, Inc., Standard BioTools Inc., Akoya Biosciences, Inc., Merck KGaA, Roche Holding AG, QIAGEN N.V., Agilent Technologies, Inc., Waters Corporation, Revvity, Inc., Sartorius AG, Oxford Nanopore Technologies plc, and Pacific Biosciences of California, Inc.

Key Developments:

In September 2026, 10x Genomics, Inc. launched a next-generation spatial transcriptomics platform optimized for high-resolution tissue mapping, achieving a thirty percent improvement in gene detection while significantly reducing sample preparation time requirements for global research laboratories.

In August 2026, Bruker Corporation expanded its mass spectrometry imaging capacity through a strategic partnership with a leading academic firm, enabling the scalable deployment of novel proteomic analysis modules for drug discovery.

In July 2026, Illumina, Inc. secured a major supply agreement to provide customized sequencing reagents for a prominent pharmaceutical company, facilitating the efficient integration of advanced multi-omic tools into next-generation therapeutic ecosystems globally.

Molecular Modalities Covered:

• Spatial Transcriptomics
• Spatial Genomics
• Spatial Proteomics
• Spatial Epigenomics
• Spatial Metabolomics
• Spatial Lipidomics
• Other Molecular Modalities

Technologies Covered:

• Sequencing-Based Technologies
• Imaging-Based Technologies
• In Situ Hybridization Technologies
• Multiplexed Imaging Technologies
• Mass Spectrometry-Based Technologies
• Hybrid Imaging-Sequencing Technologies
• Other Technologies

Multi-Omic Combinations Covered:

• Transcriptomics and Proteomics
• Transcriptomics and Genomics
• Transcriptomics and Epigenomics
• Transcriptomics, Proteomics and Genomics
• Transcriptomics, Proteomics and Epigenomics
• Transcriptomics, Proteomics and Metabolomics
• Integrated Multi-Layer Omics

Product and Services Covered:

• Instruments and Platforms
• Consumables and Reagents
• Assay Kits
• Software and Bioinformatics
• Data Analysis Services
• Sample Preparation Services
• Research and Laboratory Services

Sample Types Covered:

• Formalin-Fixed Paraffin-Embedded Samples
• Fresh Frozen Tissue
• Fresh Tissue
• Cell Suspensions
• Organotypic and 3D Tissue Models
• Liquid Biopsy Samples
• Other Sample Types

Applications Covered:

• Oncology Research
• Immunology and Immuno-Oncology
• Neuroscience
• Drug Discovery and Development
• Biomarker Discovery
• Cell Biology and Developmental Biology
• Infectious Disease Research
• Precision Medicine
• Other Applications

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Spatial Biology & Multi-Omics Market, By Molecular Modality

• 5.1 Spatial Transcriptomics
• 5.2 Spatial Genomics
• 5.3 Spatial Proteomics
• 5.4 Spatial Epigenomics
• 5.5 Spatial Metabolomics
• 5.6 Spatial Lipidomics
• 5.7 Other Molecular Modalities

6 Global Spatial Biology & Multi-Omics Market, By Technology

• 6.1 Sequencing-Based Technologies
• 6.2 Imaging-Based Technologies
• 6.3 In Situ Hybridization Technologies
• 6.4 Multiplexed Imaging Technologies
• 6.5 Mass Spectrometry-Based Technologies
• 6.6 Hybrid Imaging-Sequencing Technologies
• 6.7 Other Technologies

7 Global Spatial Biology & Multi-Omics Market, By Multi-Omic Combination

• 7.1 Transcriptomics and Proteomics
• 7.2 Transcriptomics and Genomics
• 7.3 Transcriptomics and Epigenomics
• 7.4 Transcriptomics, Proteomics and Genomics
• 7.5 Transcriptomics, Proteomics and Epigenomics
• 7.6 Transcriptomics, Proteomics and Metabolomics
• 7.7 Integrated Multi-Layer Omics

8 Global Spatial Biology & Multi-Omics Market, By Product and Service

• 8.1 Instruments and Platforms
• 8.2 Consumables and Reagents
• 8.3 Assay Kits
• 8.4 Software and Bioinformatics
• 8.5 Data Analysis Services
• 8.6 Sample Preparation Services
• 8.7 Research and Laboratory Services

9 Global Spatial Biology & Multi-Omics Market, By Sample Type

• 9.1 Formalin-Fixed Paraffin-Embedded Samples
• 9.2 Fresh Frozen Tissue
• 9.3 Fresh Tissue
• 9.4 Cell Suspensions
• 9.5 Organotypic and 3D Tissue Models
• 9.6 Liquid Biopsy Samples
• 9.7 Other Sample Types

10 Global Spatial Biology & Multi-Omics Market, By Application

• 10.1 Oncology Research
• 10.2 Immunology and Immuno-Oncology
• 10.3 Neuroscience
• 10.4 Drug Discovery and Development
• 10.5 Biomarker Discovery
• 10.6 Cell Biology and Developmental Biology
• 10.7 Infectious Disease Research
• 10.8 Precision Medicine
• 10.9 Other Applications

11 Global Spatial Biology & Multi-Omics Market, By Geography

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
  • 11.1.3 Mexico
• 11.2 Europe
  • 11.2.1 United Kingdom
  • 11.2.2 Germany
  • 11.2.3 France
  • 11.2.4 Italy
  • 11.2.5 Spain
  • 11.2.6 Netherlands
  • 11.2.7 Belgium
  • 11.2.8 Sweden
  • 11.2.9 Switzerland
  • 11.2.10 Poland
  • 11.2.11 Rest of Europe
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Australia
  • 11.3.6 Indonesia
  • 11.3.7 Thailand
  • 11.3.8 Malaysia
  • 11.3.9 Singapore
  • 11.3.10 Vietnam
  • 11.3.11 Rest of Asia Pacific
• 11.4 South America
  • 11.4.1 Brazil
  • 11.4.2 Argentina
  • 11.4.3 Colombia
  • 11.4.4 Chile
  • 11.4.5 Peru
  • 11.4.6 Rest of South America
• 11.5 Rest of the World (RoW)
  • 11.5.1 Middle East
    • 11.5.1.1 Saudi Arabia
    • 11.5.1.2 United Arab Emirates
    • 11.5.1.3 Qatar
    • 11.5.1.4 Israel
    • 11.5.1.5 Rest of Middle East
  • 11.5.2 Africa
    • 11.5.2.1 South Africa
    • 11.5.2.2 Egypt
    • 11.5.2.3 Morocco
    • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

• 12.1 Industry Value Network and Supply Chain Assessment
• 12.2 White-Space and Opportunity Mapping
• 12.3 Product Evolution and Market Life Cycle Analysis
• 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

• 13.1 Mergers and Acquisitions
• 13.2 Partnerships, Alliances, and Joint Ventures
• 13.3 New Product Launches and Certifications
• 13.4 Capacity Expansion and Investments
• 13.5 Other Strategic Initiatives

14 Company Profiles

• 14.1 10x Genomics, Inc.
• 14.2 Bruker Corporation
• 14.3 Illumina, Inc.
• 14.4 Thermo Fisher Scientific Inc.
• 14.5 Danaher Corporation
• 14.6 Quanterix Corporation
• 14.7 NanoString Technologies, Inc.
• 14.8 Standard BioTools Inc.
• 14.9 Akoya Biosciences, Inc.
• 14.10 Merck KGaA
• 14.11 Roche Holding AG
• 14.12 QIAGEN N.V.
• 14.13 Agilent Technologies, Inc.
• 14.14 Waters Corporation
• 14.15 Revvity, Inc.
• 14.16 Sartorius AG
• 14.17 Oxford Nanopore Technologies plc
• 14.18 Pacific Biosciences of California, Inc.